SSRIs and Psilocybin

This is one of the most common questions we get, and it deserves a careful answer. A lot of people who are interested in microdosing are also on antidepressants, specifically SSRIs or SNRIs. They want to know whether it is safe to combine them, whether the microdose will still work, and whether they should consider tapering off their medication.

We are not doctors. We do not give medical advice. What we can do is tell you what the research says, honestly, so you can have a better conversation with your prescriber.

How SSRIs work

SSRIs, selective serotonin reuptake inhibitors, work by blocking the reuptake of serotonin in the synaptic cleft. This means more serotonin remains available in the space between neurons for longer, which is associated with improved mood in people with depression. Common SSRIs include fluoxetine, sertraline, escitalopram, and paroxetine.

SNRIs, serotonin-norepinephrine reuptake inhibitors, do the same for both serotonin and norepinephrine. Common SNRIs include venlafaxine and duloxetine.

Both classes of medication, when taken regularly, cause a gradual downregulation of serotonin receptors, including the 5-HT2A receptor. Over weeks and months of consistent use, the brain adjusts to the elevated serotonin by reducing the number and sensitivity of the receptors that respond to it.

How psilocybin works, and why the overlap matters

Psilocybin works primarily by binding to the 5-HT2A serotonin receptor. This is the same receptor family that SSRIs influence through receptor downregulation. Because people on long-term SSRIs have a reduced number and sensitivity of 5-HT2A receptors, psilocybin has fewer and less sensitive targets to bind to.

The result, consistently reported in both research and anecdotal accounts, is that SSRIs blunt the effect of psilocybin significantly. At macro doses, this is well documented. At microdose levels, the practical consequence is that many people on SSRIs find their microdose has little to no perceptible effect.

Is it dangerous to combine them?

The combination of SSRIs and psilocybin is not generally considered medically dangerous at standard doses. There is no documented case of serotonin syndrome from the combination at therapeutic levels, which is a common concern people raise. Serotonin syndrome typically requires a more substantial serotonergic excess than psilocybin at sub-perceptual doses would contribute.

The more significant risks are different. First, because the effect of psilocybin is blunted, there is a risk of dose-escalation, taking more because you feel nothing, which moves you into higher-dose territory with less predictable effects. Second, there are individual pharmacological variations that make general safety claims hard to apply universally.

This is why the first and most important thing to do is talk to your doctor. Not as a formality, as a genuine consultation about your specific medication, dose, history, and what you are trying to accomplish.

The question of tapering

Some people who want to microdose and are on SSRIs consider tapering off their medication under medical supervision before beginning a protocol. This is a legitimate clinical consideration that some prescribers are willing to have, particularly as the research on psilocybin and depression advances.

We make no recommendation about tapering. That is a decision that belongs between you and your prescriber, who knows your history, your diagnosis, and the trajectory of your mental health. What we can say is that the conversation is worth having if microdosing is something you are serious about.

If your prescriber is not familiar with psilocybin research, the literature from Johns Hopkins, Imperial College London, and NYU on psilocybin for treatment-resistant depression is a reasonable starting point for that conversation.

What about MAO inhibitors and other medications?

MAO inhibitors, or MAOIs, are a different class of antidepressant and carry a higher interaction risk with psilocybin. The combination can potentiate psilocybin's effects significantly and unpredictably. Do not combine psilocybin with MAOIs.

Lithium is another medication that should not be combined with psilocybin. There are documented cases of seizure from this combination, even at doses that would typically be considered low.

Tramadol, an opioid pain medication with serotonergic activity, also warrants caution. The interaction potential is not as well characterized as lithium, but the harm-reduction consensus is to avoid the combination.

The bottom line

If you are on an SSRI or SNRI and want to microdose, the two most important things to do are talk to your doctor and set realistic expectations. Your microdose may feel like nothing at first. It may take a different dose tier to feel anything at all. And the conversation about whether to continue, adjust, or taper your medication is one that deserves careful medical thought, not a decision made unilaterally based on what you read on the internet, including here.